GENERALIZABILITY OF CLINICAL TRIAL RESULTS FOR GENERALIZED ANXIETY DISORDER TO COMMUNITY SAMPLES

Authors

  • Nicolas Hoertel,

    1. Service de psychiatrie, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris (APHP), Colombes, France
    2. Centre Psychiatrie et Neurosciences, Inserm, U894, Université Paris Descartes, Paris, France
    Search for more papers by this author
  • Yann Le Strat,

    Corresponding author
    1. Centre Psychiatrie et Neurosciences, Inserm, U894, Université Paris Descartes, Paris, France
    2. Université Paris Diderot, Sorbonne, Faculté de médecine Bichat-Lariboisière, Paris, France
    • Service de psychiatrie, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris (APHP), Colombes, France
    Search for more papers by this author
  • Carlos Blanco,

    1. Columbia University and the New York State Psychiatric Institute, New York, NY
    Search for more papers by this author
  • Pierre Lavaud,

    1. Service de psychiatrie, Hôpital Kremlin Bicêtre, Assistance Publique-Hôpitaux de Paris, (AP-HP), Paris, France
    Search for more papers by this author
  • Caroline Dubertret

    1. Service de psychiatrie, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris (APHP), Colombes, France
    2. Centre Psychiatrie et Neurosciences, Inserm, U894, Université Paris Descartes, Paris, France
    3. Université Paris Diderot, Sorbonne, Faculté de médecine Bichat-Lariboisière, Paris, France
    Search for more papers by this author

  • We declare that we have no conflict of interest.

Correspondence to: Yann Le Strat, Service de psychiatrie, Hôpital Louis Mourier, Assistance Publique-Hôpitaux de Paris (AP-HP), Colombes, France.

E-mail: yann.lestrat@inserm.fr

Abstract

Background

There has been little research on the generalizability of clinical trials for generalized anxiety disorder (GAD). The present study examines the generalizability of pharmacological and psychotherapy clinical trials’ results of individuals with DSM-IV GAD to a large community sample.

Methods

Data were drawn from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC), a large national representative face-to-face sample of 43,093 adults of the United States population. We applied a standard set of eligibility criteria representative of GAD pharmacological and psychotherapy clinical trials to all adults with past 12 months GAD (n = 894), and to a subgroup of participants seeking treatment (n = 329). Our aim was to assess how many participants with GAD would fulfil typical eligibility criteria.

Results

We found that more than seven out of 10 participants with GAD were excluded by at least one criterion. In the subgroup of GAD participants who sought treatment, the exclusion rate by at least one criterion raised to more than eight out of 10 participants with GAD. For the overall sample and the treatment-seeking subsample, having a current depression was the criterion excluding the highest percentage of individuals. Having a lifetime history of bipolar disorder, a current significant medical condition, a current diagnosis of alcohol abuse or dependence, and a social or specific phobia also excluded a substantial proportion of individuals in both samples.

Conclusions

Clinical trials exclude a majority of adults with GAD. Clinical trials should carefully consider the impact of eligibility criteria on the generalizability of their results. Depression and Anxiety 00:1–7, 2012. © 2012 Wiley Periodicals, Inc.

Ancillary